Неканоническое влияние ингибиторов тирозинкиназ для терапии злокачественных опухолей на экспрессию генов
https://doi.org/10.25557/2073-7998.2021.12.34-39
Аннотация
Об авторах
А. Ю. КузевановаРоссия
А. В. Карпухин
Россия
А. А. Алимов
Россия
Список литературы
1. Mahvi D.A., Liu R., Grinstaff M.W., Colson Y.L., Raut C.P. Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies. CA Cancer J Clin. 2018;68(6):488-505. doi:10.3322/caac.21498
2. Huang L., Jiang S., Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol. 2020;13(1):143. doi:10.1186/s13045-020-00977-0
3. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007;6(9):734-745. doi:10.1038/nrd2380
4. López de Andrés J., Griñán-Lisón C., Jiménez G., Marchal J.A. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J Hematol Oncol. 2020;13(1):136. doi:10.1186/s13045-020-00966-3
5. Zhu L., Jiang M., Wang H., et al. A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Ann Transl Med. 2021;9(16):1351. doi:10.21037/atm-21-1948
6. Yang J., Antin.P, Berx G., et al. Guidelines and definitions for research on epithelial-mesenchymal transition [published correction appears in Nat Rev Mol Cell Biol. 2021 Dec;22(12):834]. Nat Rev Mol Cell Biol. 2020;21(6):341-352. doi:10.1038/s41580-020-0237-9
7. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178-196. doi:10.1038/nrm3758
8. Hwang H.S., Go H., Park J.M., et al. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma. Lab Invest. 2019;99(5):659-670. doi:10.1038/s41374-019-0188-y
9. Hwang H.S., Go H., Park J.M., et al. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma. Lab Invest. 2019;99(5):659-670. doi:10.1038/s41374-019-0188-y
Рецензия
Для цитирования:
Кузеванова А.Ю., Карпухин А.В., Алимов А.А. Неканоническое влияние ингибиторов тирозинкиназ для терапии злокачественных опухолей на экспрессию генов. Медицинская генетика. 2021;20(12):34-39. https://doi.org/10.25557/2073-7998.2021.12.34-39
For citation:
Kuzevanova A.Yu., Karpukhin A.V., Alimov A.A. The non-canonical effect of tyrosine kinase inhibitors for the treatment of malignant tumors on gene expression. Medical Genetics. 2021;20(12):34-39. (In Russ.) https://doi.org/10.25557/2073-7998.2021.12.34-39